0001209191-23-007782.txt : 20230208
0001209191-23-007782.hdr.sgml : 20230208
20230208162204
ACCESSION NUMBER: 0001209191-23-007782
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230206
FILED AS OF DATE: 20230208
DATE AS OF CHANGE: 20230208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jorgensen Nathan D.
CENTRAL INDEX KEY: 0001842523
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39979
FILM NUMBER: 23599361
MAIL ADDRESS:
STREET 1: C/O VOR BIOPHARMA INC.
STREET 2: 100 CAMBRIDGEPARK DRIVE, SUITE 400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vor Biopharma Inc.
CENTRAL INDEX KEY: 0001817229
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 101
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-655-6580
MAIL ADDRESS:
STREET 1: 100 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 101
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-06
0
0001817229
Vor Biopharma Inc.
VOR
0001842523
Jorgensen Nathan D.
C/O VOR BIOPHARMA INC.
100 CAMBRIDGEPARK DRIVE, SUITE 101
CAMBRIDGE
MA
02140
0
1
0
0
Chief Financial Officer
Common Stock
2023-02-06
4
A
0
45500
0.00
A
160769
D
Employee Stock Option (right to buy)
5.55
2023-02-06
4
A
0
91000
0.00
A
2033-02-05
Common Stock
91000
91000
D
Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date.
The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.
/s/ Rich Segal, Attorney-in-Fact
2023-02-08